Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

DiaMedica Therapeutics (DMAC) Leases (2019 - 2026)

DiaMedica Therapeutics filings provide 8 years of Leases readings, the most recent being $175000.0 for Q1 2026.

  • Quarterly Leases fell 32.43% to $175000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $175000.0 through Mar 2026, down 32.43% year-over-year, with the annual reading at $197000.0 for FY2025, 29.39% down from the prior year.
  • Leases hit $175000.0 in Q1 2026 for DiaMedica Therapeutics, down from $197000.0 in the prior quarter.
  • Across five years, Leases topped out at $446000.0 in Q2 2022 and bottomed at $26000.0 in Q1 2022.
  • Average Leases over 5 years is $304588.2, with a median of $317000.0 recorded in 2024.
  • The largest annual shift saw Leases plummeted 69.77% in 2022 before it skyrocketed 1465.38% in 2023.
  • DiaMedica Therapeutics' Leases stood at $424000.0 in 2022, then decreased by 16.51% to $354000.0 in 2023, then decreased by 21.19% to $279000.0 in 2024, then dropped by 29.39% to $197000.0 in 2025, then dropped by 11.17% to $175000.0 in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Leases are $175000.0 (Q1 2026), $197000.0 (Q4 2025), and $218000.0 (Q3 2025).